One-year outcomes of the da VINCI study of VEGF trap-eye in eyes with diabetic macular edema

Diana V. Do, Quan Dong Nguyen, David Boyer, Ursula Schmidt-Erfurth, David M. Brown, Robert Vitti, Alyson J. Berliner, Bo Gao, Oliver Zeitz, Rene Ruckert, Thomas Schmelter, Rupert Sandbrink, Jeff S. Heier

Research output: Contribution to journalArticle

229 Citations (Scopus)

Abstract

Purpose: To compare different doses and dosing regimens of Vascular Endothelial Growth Factor (VEGF) Trap-Eye with laser photocoagulation in eyes with diabetic macular edema (DME). Design: Randomized, double-masked, multicenter, phase 2 clinical trial. Participants: Diabetic patients (n = 221) with center-involved DME. Methods: Participants were assigned randomly to 1 of 5 treatment regimens: VEGF Trap-Eye 0.5 mg every 4 weeks (0.5q4); 2 mg every 4 weeks (2q4); 2 mg every 8 weeks after 3 initial monthly doses (2q8); or 2 mg dosing as needed after 3 initial monthly doses (2PRN), or macular laser photocoagulation. Main Outcome Measures: The change in best-corrected visual acuity (BCVA) at 24 weeks (the primary end point) and at 52 weeks, proportion of eyes that gained 15 letters or more in Early Treatment of Diabetic Retinopathy Study (ETDRS) BCVA, and mean changes in central retinal thickness (CRT) from baseline. Results: As previously reported, mean improvements in BCVA in the VEGF Trap-Eye groups at week 24 were 8.6, 11.4, 8.5, and 10.3 letters for 0.5q4, 2q4, 2q8, and 2PRN regimens, respectively, versus 2.5 letters for the laser group (P ≤ 0.0085 versus laser). Mean improvements in BCVA in the VEGF Trap-Eye groups at week 52 were 11.0, 13.1, 9.7, and 12.0 letters for 0.5q4, 2q4, 2q8, and 2PRN regimens, respectively, versus -1.3 letters for the laser group (P ≤ 0.0001 versus laser). Proportions of eyes with gains in BCVA of 15 or more ETDRS letters at week 52 in the VEGF Trap-Eye groups were 40.9%, 45.5%, 23.8%, and 42.2% versus 11.4% for laser (P = 0.0031, P = 0.0007, P = 0.1608, and P = 0.0016, respectively, versus laser). Mean reductions in CRT in the VEGF Trap-Eye groups at week 52 were -165.4 μm, -227.4 μm, -187.8 μm, and -180.3 μm versus -58.4 μm for laser (P < 0.0001 versus laser). Vascular Endothelial Growth Factor Trap-Eye generally was well tolerated. The most frequent ocular adverse events with VEGF Trap-Eye were conjunctival hemorrhage, eye pain, ocular hyperemia, and increased intraocular pressure, whereas common systemic adverse events included hypertension, nausea, and congestive heart failure. Conclusions: Significant gains in BCVA from baseline achieved at week 24 were maintained or improved at week 52 in all VEGF Trap-Eye groups. Vascular Endothelial Growth Factor Trap-Eye warrants further investigation for the treatment of DME. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

Original languageEnglish (US)
Pages (from-to)1658-1665
Number of pages8
JournalOphthalmology
Volume119
Issue number8
DOIs
StatePublished - Aug 1 2012

Fingerprint

Macular Edema
Vascular Endothelial Growth Factor A
Lasers
Visual Acuity
Light Coagulation
Disclosure
Diabetic Retinopathy
Eye Pain
Hyperemia
Therapeutics
Intraocular Pressure
Nausea

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Do, D. V., Nguyen, Q. D., Boyer, D., Schmidt-Erfurth, U., Brown, D. M., Vitti, R., ... Heier, J. S. (2012). One-year outcomes of the da VINCI study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology, 119(8), 1658-1665. https://doi.org/10.1016/j.ophtha.2012.02.010

One-year outcomes of the da VINCI study of VEGF trap-eye in eyes with diabetic macular edema. / Do, Diana V.; Nguyen, Quan Dong; Boyer, David; Schmidt-Erfurth, Ursula; Brown, David M.; Vitti, Robert; Berliner, Alyson J.; Gao, Bo; Zeitz, Oliver; Ruckert, Rene; Schmelter, Thomas; Sandbrink, Rupert; Heier, Jeff S.

In: Ophthalmology, Vol. 119, No. 8, 01.08.2012, p. 1658-1665.

Research output: Contribution to journalArticle

Do, DV, Nguyen, QD, Boyer, D, Schmidt-Erfurth, U, Brown, DM, Vitti, R, Berliner, AJ, Gao, B, Zeitz, O, Ruckert, R, Schmelter, T, Sandbrink, R & Heier, JS 2012, 'One-year outcomes of the da VINCI study of VEGF trap-eye in eyes with diabetic macular edema', Ophthalmology, vol. 119, no. 8, pp. 1658-1665. https://doi.org/10.1016/j.ophtha.2012.02.010
Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R et al. One-year outcomes of the da VINCI study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology. 2012 Aug 1;119(8):1658-1665. https://doi.org/10.1016/j.ophtha.2012.02.010
Do, Diana V. ; Nguyen, Quan Dong ; Boyer, David ; Schmidt-Erfurth, Ursula ; Brown, David M. ; Vitti, Robert ; Berliner, Alyson J. ; Gao, Bo ; Zeitz, Oliver ; Ruckert, Rene ; Schmelter, Thomas ; Sandbrink, Rupert ; Heier, Jeff S. / One-year outcomes of the da VINCI study of VEGF trap-eye in eyes with diabetic macular edema. In: Ophthalmology. 2012 ; Vol. 119, No. 8. pp. 1658-1665.
@article{a9e4f4f451334a34bd19dfa81c087cfd,
title = "One-year outcomes of the da VINCI study of VEGF trap-eye in eyes with diabetic macular edema",
abstract = "Purpose: To compare different doses and dosing regimens of Vascular Endothelial Growth Factor (VEGF) Trap-Eye with laser photocoagulation in eyes with diabetic macular edema (DME). Design: Randomized, double-masked, multicenter, phase 2 clinical trial. Participants: Diabetic patients (n = 221) with center-involved DME. Methods: Participants were assigned randomly to 1 of 5 treatment regimens: VEGF Trap-Eye 0.5 mg every 4 weeks (0.5q4); 2 mg every 4 weeks (2q4); 2 mg every 8 weeks after 3 initial monthly doses (2q8); or 2 mg dosing as needed after 3 initial monthly doses (2PRN), or macular laser photocoagulation. Main Outcome Measures: The change in best-corrected visual acuity (BCVA) at 24 weeks (the primary end point) and at 52 weeks, proportion of eyes that gained 15 letters or more in Early Treatment of Diabetic Retinopathy Study (ETDRS) BCVA, and mean changes in central retinal thickness (CRT) from baseline. Results: As previously reported, mean improvements in BCVA in the VEGF Trap-Eye groups at week 24 were 8.6, 11.4, 8.5, and 10.3 letters for 0.5q4, 2q4, 2q8, and 2PRN regimens, respectively, versus 2.5 letters for the laser group (P ≤ 0.0085 versus laser). Mean improvements in BCVA in the VEGF Trap-Eye groups at week 52 were 11.0, 13.1, 9.7, and 12.0 letters for 0.5q4, 2q4, 2q8, and 2PRN regimens, respectively, versus -1.3 letters for the laser group (P ≤ 0.0001 versus laser). Proportions of eyes with gains in BCVA of 15 or more ETDRS letters at week 52 in the VEGF Trap-Eye groups were 40.9{\%}, 45.5{\%}, 23.8{\%}, and 42.2{\%} versus 11.4{\%} for laser (P = 0.0031, P = 0.0007, P = 0.1608, and P = 0.0016, respectively, versus laser). Mean reductions in CRT in the VEGF Trap-Eye groups at week 52 were -165.4 μm, -227.4 μm, -187.8 μm, and -180.3 μm versus -58.4 μm for laser (P < 0.0001 versus laser). Vascular Endothelial Growth Factor Trap-Eye generally was well tolerated. The most frequent ocular adverse events with VEGF Trap-Eye were conjunctival hemorrhage, eye pain, ocular hyperemia, and increased intraocular pressure, whereas common systemic adverse events included hypertension, nausea, and congestive heart failure. Conclusions: Significant gains in BCVA from baseline achieved at week 24 were maintained or improved at week 52 in all VEGF Trap-Eye groups. Vascular Endothelial Growth Factor Trap-Eye warrants further investigation for the treatment of DME. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.",
author = "Do, {Diana V.} and Nguyen, {Quan Dong} and David Boyer and Ursula Schmidt-Erfurth and Brown, {David M.} and Robert Vitti and Berliner, {Alyson J.} and Bo Gao and Oliver Zeitz and Rene Ruckert and Thomas Schmelter and Rupert Sandbrink and Heier, {Jeff S.}",
year = "2012",
month = "8",
day = "1",
doi = "10.1016/j.ophtha.2012.02.010",
language = "English (US)",
volume = "119",
pages = "1658--1665",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - One-year outcomes of the da VINCI study of VEGF trap-eye in eyes with diabetic macular edema

AU - Do, Diana V.

AU - Nguyen, Quan Dong

AU - Boyer, David

AU - Schmidt-Erfurth, Ursula

AU - Brown, David M.

AU - Vitti, Robert

AU - Berliner, Alyson J.

AU - Gao, Bo

AU - Zeitz, Oliver

AU - Ruckert, Rene

AU - Schmelter, Thomas

AU - Sandbrink, Rupert

AU - Heier, Jeff S.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Purpose: To compare different doses and dosing regimens of Vascular Endothelial Growth Factor (VEGF) Trap-Eye with laser photocoagulation in eyes with diabetic macular edema (DME). Design: Randomized, double-masked, multicenter, phase 2 clinical trial. Participants: Diabetic patients (n = 221) with center-involved DME. Methods: Participants were assigned randomly to 1 of 5 treatment regimens: VEGF Trap-Eye 0.5 mg every 4 weeks (0.5q4); 2 mg every 4 weeks (2q4); 2 mg every 8 weeks after 3 initial monthly doses (2q8); or 2 mg dosing as needed after 3 initial monthly doses (2PRN), or macular laser photocoagulation. Main Outcome Measures: The change in best-corrected visual acuity (BCVA) at 24 weeks (the primary end point) and at 52 weeks, proportion of eyes that gained 15 letters or more in Early Treatment of Diabetic Retinopathy Study (ETDRS) BCVA, and mean changes in central retinal thickness (CRT) from baseline. Results: As previously reported, mean improvements in BCVA in the VEGF Trap-Eye groups at week 24 were 8.6, 11.4, 8.5, and 10.3 letters for 0.5q4, 2q4, 2q8, and 2PRN regimens, respectively, versus 2.5 letters for the laser group (P ≤ 0.0085 versus laser). Mean improvements in BCVA in the VEGF Trap-Eye groups at week 52 were 11.0, 13.1, 9.7, and 12.0 letters for 0.5q4, 2q4, 2q8, and 2PRN regimens, respectively, versus -1.3 letters for the laser group (P ≤ 0.0001 versus laser). Proportions of eyes with gains in BCVA of 15 or more ETDRS letters at week 52 in the VEGF Trap-Eye groups were 40.9%, 45.5%, 23.8%, and 42.2% versus 11.4% for laser (P = 0.0031, P = 0.0007, P = 0.1608, and P = 0.0016, respectively, versus laser). Mean reductions in CRT in the VEGF Trap-Eye groups at week 52 were -165.4 μm, -227.4 μm, -187.8 μm, and -180.3 μm versus -58.4 μm for laser (P < 0.0001 versus laser). Vascular Endothelial Growth Factor Trap-Eye generally was well tolerated. The most frequent ocular adverse events with VEGF Trap-Eye were conjunctival hemorrhage, eye pain, ocular hyperemia, and increased intraocular pressure, whereas common systemic adverse events included hypertension, nausea, and congestive heart failure. Conclusions: Significant gains in BCVA from baseline achieved at week 24 were maintained or improved at week 52 in all VEGF Trap-Eye groups. Vascular Endothelial Growth Factor Trap-Eye warrants further investigation for the treatment of DME. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

AB - Purpose: To compare different doses and dosing regimens of Vascular Endothelial Growth Factor (VEGF) Trap-Eye with laser photocoagulation in eyes with diabetic macular edema (DME). Design: Randomized, double-masked, multicenter, phase 2 clinical trial. Participants: Diabetic patients (n = 221) with center-involved DME. Methods: Participants were assigned randomly to 1 of 5 treatment regimens: VEGF Trap-Eye 0.5 mg every 4 weeks (0.5q4); 2 mg every 4 weeks (2q4); 2 mg every 8 weeks after 3 initial monthly doses (2q8); or 2 mg dosing as needed after 3 initial monthly doses (2PRN), or macular laser photocoagulation. Main Outcome Measures: The change in best-corrected visual acuity (BCVA) at 24 weeks (the primary end point) and at 52 weeks, proportion of eyes that gained 15 letters or more in Early Treatment of Diabetic Retinopathy Study (ETDRS) BCVA, and mean changes in central retinal thickness (CRT) from baseline. Results: As previously reported, mean improvements in BCVA in the VEGF Trap-Eye groups at week 24 were 8.6, 11.4, 8.5, and 10.3 letters for 0.5q4, 2q4, 2q8, and 2PRN regimens, respectively, versus 2.5 letters for the laser group (P ≤ 0.0085 versus laser). Mean improvements in BCVA in the VEGF Trap-Eye groups at week 52 were 11.0, 13.1, 9.7, and 12.0 letters for 0.5q4, 2q4, 2q8, and 2PRN regimens, respectively, versus -1.3 letters for the laser group (P ≤ 0.0001 versus laser). Proportions of eyes with gains in BCVA of 15 or more ETDRS letters at week 52 in the VEGF Trap-Eye groups were 40.9%, 45.5%, 23.8%, and 42.2% versus 11.4% for laser (P = 0.0031, P = 0.0007, P = 0.1608, and P = 0.0016, respectively, versus laser). Mean reductions in CRT in the VEGF Trap-Eye groups at week 52 were -165.4 μm, -227.4 μm, -187.8 μm, and -180.3 μm versus -58.4 μm for laser (P < 0.0001 versus laser). Vascular Endothelial Growth Factor Trap-Eye generally was well tolerated. The most frequent ocular adverse events with VEGF Trap-Eye were conjunctival hemorrhage, eye pain, ocular hyperemia, and increased intraocular pressure, whereas common systemic adverse events included hypertension, nausea, and congestive heart failure. Conclusions: Significant gains in BCVA from baseline achieved at week 24 were maintained or improved at week 52 in all VEGF Trap-Eye groups. Vascular Endothelial Growth Factor Trap-Eye warrants further investigation for the treatment of DME. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

UR - http://www.scopus.com/inward/record.url?scp=84864444516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864444516&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2012.02.010

DO - 10.1016/j.ophtha.2012.02.010

M3 - Article

C2 - 22537617

AN - SCOPUS:84864444516

VL - 119

SP - 1658

EP - 1665

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 8

ER -